Relmada Aces REL-1017 Vs Ketamine Study For Abuse Potential

Relmada Therapeutics Inc RLMD has announced topline results of the human abuse potential (HAP) study with REL-1017 for major depressive disorder or MDD.

• REL-1017 is a novel NMDA receptor (NMDAR) channel blocker and the Company's lead candidate.
• The results showed that all three doses of REL-1017 (25 mg, 75 mg, and 150 mg) tested in recreational drug users demonstrated a substantial (30+ points) and statistically significant difference vs. intravenous ketamine 0.5 mg/kg over 40 minutes and were statistically equivalent to placebo.
• Related: Relmada Stock Falls After Equity Raise Of $150M To Fund Depression Candidate.
• Sergio Traversa, CEO of Relmada Therapeutics, said the results demonstrated that REL-1017 strongly differentiates from ketamine and is comparable to placebo for the maximum effect for Drug Liking 'at this moment." 
• The data are consistent with previously generated results of the REL-1017 vs. oxycodone HAP study, which showed no meaningful abuse potential on the opioid domain.
• Price Action: RLMD shares are up 7.06% at $19.56 during the market session on the last check Wednesday.